Loading...

Karyopharm Therapeutics

DB:25K
Snowflake Description

High growth potential with adequate balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
25K
DB
$296M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. The last earnings update was 55 days ago. More info.


Add to Portfolio Compare Print
  • Karyopharm Therapeutics has significant price volatility in the past 3 months.
25K Share Price and Events
7 Day Returns
-1.8%
DB:25K
-0.1%
DE Biotechs
1%
DE Market
1 Year Returns
-60.3%
DB:25K
-7.4%
DE Biotechs
-5.6%
DE Market
25K Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Karyopharm Therapeutics (25K) -1.8% -7.9% -43.5% -60.3% -47.5% -75.9%
DE Biotechs -0.1% 6% -6.7% -7.4% 53.2% 11.6%
DE Market 1% 6.1% 8.4% -5.6% 10.9% 13.8%
1 Year Return vs Industry and Market
  • 25K underperformed the Biotechs industry which returned -7.4% over the past year.
  • 25K underperformed the Market in Germany which returned -5.6% over the past year.
Price Volatility
25K
Industry
5yr Volatility vs Market
Related Companies

25K Value

 Is Karyopharm Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Karyopharm Therapeutics to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Karyopharm Therapeutics.

DB:25K Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 8 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 9.6%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:25K
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.45
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.453 (1 + (1- 21%) (34.71%))
1.57
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.57
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.57 * 5.96%)
9.59%

Discounted Cash Flow Calculation for DB:25K using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Karyopharm Therapeutics is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:25K DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 9.59%)
2019 -200.20 Analyst x2 -182.69
2020 -226.85 Analyst x2 -188.89
2021 -151.95 Analyst x2 -115.46
2022 -57.80 Analyst x1 -40.08
2023 107.35 Analyst x2 67.92
2024 168.07 Est @ 56.56% 97.03
2025 234.73 Est @ 39.66% 123.66
2026 300.05 Est @ 27.83% 144.25
2027 358.72 Est @ 19.55% 157.37
2028 408.05 Est @ 13.75% 163.35
Present value of next 10 years cash flows $226.47
DB:25K DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $408.05 × (1 + 0.23%) ÷ (9.59% – 0.23%)
$4,369.85
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $4,369.85 ÷ (1 + 9.59%)10
$1,749.31
DB:25K Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $226.47 + $1,749.31
$1,975.79
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $1,975.79 / 60.86
$32.46
DB:25K Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:25K represents 0.89465x of NasdaqGS:KPTI
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.89465x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 32.46 x 0.89465
€29.04
Value per share (EUR) From above. €29.04
Current discount Discount to share price of €4.35
= -1 x (€4.35 - €29.04) / €29.04
85%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Karyopharm Therapeutics is available for.
Intrinsic value
>50%
Share price is €4.35 vs Future cash flow value of €29.04
Current Discount Checks
For Karyopharm Therapeutics to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Karyopharm Therapeutics's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Karyopharm Therapeutics's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Karyopharm Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Karyopharm Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:25K PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-3.14
NasdaqGS:KPTI Share Price ** NasdaqGS (2019-04-24) in USD $4.86
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.73x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.72x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Karyopharm Therapeutics.

DB:25K PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:KPTI Share Price ÷ EPS (both in USD)

= 4.86 ÷ -3.14

-1.55x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Karyopharm Therapeutics is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Karyopharm Therapeutics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Karyopharm Therapeutics's expected growth come at a high price?
Raw Data
DB:25K PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.55x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 8 Analysts
24.9%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 269 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Karyopharm Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Karyopharm Therapeutics's assets?
Raw Data
DB:25K PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $3.01
NasdaqGS:KPTI Share Price * NasdaqGS (2019-04-24) in USD $4.86
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.72x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.87x
DB:25K PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:KPTI Share Price ÷ Book Value per Share (both in USD)

= 4.86 ÷ 3.01

1.61x

* Primary Listing of Karyopharm Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Karyopharm Therapeutics is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Karyopharm Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Karyopharm Therapeutics has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

25K Future Performance

 How is Karyopharm Therapeutics expected to perform in the next 1 to 3 years based on estimates from 8 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
24.9%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Karyopharm Therapeutics expected to grow at an attractive rate?
  • Karyopharm Therapeutics's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Karyopharm Therapeutics's earnings growth is expected to exceed the Germany market average.
  • Karyopharm Therapeutics's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:25K Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:25K Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 8 Analysts 24.9%
DB:25K Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 8 Analysts 44.4%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.6%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:25K Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:25K Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 360 116 42 3
2022-12-31 230 62 -59 3
2021-12-31 92 -129 -163 6
2020-12-31 31 -133 -210 8
2019-12-31 10 -151 -220 7
DB:25K Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 30 -159 -178
2018-09-30 32 -116 -159
2018-06-30 31 -100 -142
2018-03-31 12 -84 -138
2017-12-31 2 -74 -129
2017-09-30 0 -88 -117
2017-06-30 0 -87 -112
2017-03-31 0 -86 -112
2016-12-31 0 -84 -110
2016-09-30 0 -85 -112
2016-06-30 0 -90 -117
2016-03-31 0 -97 -119

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Karyopharm Therapeutics's earnings are expected to grow significantly at over 20% yearly.
  • Karyopharm Therapeutics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:25K Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below

All data from Karyopharm Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:25K Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 0.41 0.99 -0.21 3.00
2022-12-31 -0.58 -0.45 -0.81 3.00
2021-12-31 -2.08 -1.29 -4.32 6.00
2020-12-31 -2.96 -1.68 -4.16 9.00
2019-12-31 -3.59 -2.75 -4.08 9.00
DB:25K Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -3.14
2018-09-30 -2.96
2018-06-30 -2.81
2018-03-31 -2.88
2017-12-31 -2.81
2017-09-30 -2.65
2017-06-30 -2.69
2017-03-31 -2.88
2016-12-31 -2.92
2016-09-30 -3.09
2016-06-30 -3.26
2016-03-31 -3.33

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Karyopharm Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Karyopharm Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Karyopharm Therapeutics has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

25K Past Performance

  How has Karyopharm Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Karyopharm Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Karyopharm Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Karyopharm Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Karyopharm Therapeutics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Karyopharm Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Karyopharm Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:25K Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 30.34 -178.41 48.85
2018-09-30 31.66 -159.24 36.23
2018-06-30 31.43 -141.79 29.08
2018-03-31 11.54 -137.53 26.23
2017-12-31 1.61 -128.98 24.87
2017-09-30 0.12 -116.88 25.26
2017-06-30 0.17 -111.66 25.34
2017-03-31 0.22 -112.44 24.66
2016-12-31 0.15 -109.58 23.95
2016-09-30 0.13 -111.69 22.67
2016-06-30 0.16 -116.64 21.54
2016-03-31 0.25 -119.17 21.74
2015-12-31 0.25 -118.18 21.58
2015-09-30 0.24 -115.06 22.24
2015-06-30 0.19 -104.41 21.29
2015-03-31 0.06 -88.15 18.44
2014-12-31 0.23 -75.78 15.95
2014-09-30 0.24 -62.00 12.51
2014-06-30 0.21 -51.59 10.28
2014-03-31 0.33 -42.03 7.91
2013-12-31 0.39 -33.95 5.89
2013-09-30 0.40 -26.04 4.01
2013-06-30 0.43 -20.35 3.10
2013-03-31 0.58 -17.49 2.73
2012-12-31 0.63 -15.89 2.43

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Karyopharm Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Karyopharm Therapeutics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Karyopharm Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Karyopharm Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Karyopharm Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

25K Health

 How is Karyopharm Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Karyopharm Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Karyopharm Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Karyopharm Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Karyopharm Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 3.3x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Karyopharm Therapeutics Company Filings, last reported 3 months ago.

DB:25K Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 183.17 102.66 328.20
2018-09-30 171.08 0.00 206.77
2018-06-30 213.47 0.00 241.12
2018-03-31 95.53 0.00 130.92
2017-12-31 129.46 0.00 146.47
2017-09-30 141.18 0.00 119.41
2017-06-30 166.71 0.00 143.45
2017-03-31 138.36 0.00 109.88
2016-12-31 162.24 0.00 129.55
2016-09-30 166.93 0.00 126.81
2016-06-30 153.57 0.00 122.74
2016-03-31 177.04 0.00 136.42
2015-12-31 198.37 0.00 175.63
2015-09-30 220.59 0.00 195.24
2015-06-30 247.33 0.00 221.19
2015-03-31 275.53 0.00 246.41
2014-12-31 206.79 0.00 205.72
2014-09-30 227.80 0.00 227.13
2014-06-30 131.68 0.00 132.31
2014-03-31 144.10 0.00 144.89
2013-12-31 154.93 0.00 155.97
2013-09-30 51.91 0.00 52.93
2013-06-30 59.94 0.00 60.64
2013-03-31 -0.62 0.00 0.38
2012-12-31 -0.62 0.00 0.38
  • Karyopharm Therapeutics's level of debt (56%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0% vs 56% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Karyopharm Therapeutics has sufficient cash runway for 2 years based on current free cash flow.
  • Karyopharm Therapeutics has sufficient cash runway for 1.9 years if free cash flow continues to grow at historical rates of 11.7% each year.
X
Financial health checks
We assess Karyopharm Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Karyopharm Therapeutics has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

25K Dividends

 What is Karyopharm Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Karyopharm Therapeutics dividends. Estimated to be 0% next year.
If you bought €2,000 of Karyopharm Therapeutics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Karyopharm Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Karyopharm Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:25K Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:25K Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Karyopharm Therapeutics has not reported any payouts.
  • Unable to verify if Karyopharm Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Karyopharm Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Karyopharm Therapeutics has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Karyopharm Therapeutics's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Karyopharm Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Karyopharm Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Karyopharm Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

25K Management

 What is the CEO of Karyopharm Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Michael Kauffman
COMPENSATION $2,651,113
AGE 55
TENURE AS CEO 8.3 years
CEO Bio

Dr. Michael G. Kauffman, M.D., Ph.D. serves as Advisor at Prime Movers Lab and co-founded Karyopharm Therapeutics Inc. in 2008 and has been its Chief Executive Officer since January 05, 2011. Dr. Kauffman served as President at Karyopharm Therapeutics Inc. from January 2011 to December 2013 and Chief Medical Officer since December 2012 until December 2013. He serves as President of OutlineMed Inc. He served as the Consultant of Onyx Pharmaceuticals, Inc. since December 31, 2010. He served as Clinical Advisor at Karyopharm Therapeutics, Inc. He serves as a Director of Metamark Genetics, Inc. Dr. Kauffman served as an Interim Executive Director of Metamark Genetics, Inc. until April 2013. Dr. Kauffman serves as Director of Kezar Life Sciences, Inc. since December 2016. Dr. Kauffman served as the Chief Medical Officer at Onyx Pharmaceuticals, Inc. from November 2009 to December 31, 2010 and served as its Interim Chief Medical Officer from November 2009 to February 1, 2010. He has more than a decade of experience in drug discovery and development to the firm. Dr. Kauffman has over ten years of extensive experience in drug discovery and development. He served as the Chief Medical Officer of Proteolix Pharmaceuticals from November 2008 to November 2009, where he oversaw the clinical development of carfilzomib. At Proteolix, he led the development of Kyprolis® (carfilzomib), a novel proteasome inhibitor approved in refractory myeloma by the Food and Drug Administration in July 2012. He was the Chief Medical Officer at Onyx Therapeutics, Inc. from November 2009 to December 2010 and was responsible for the advancement of carfilzomib for the treatment of multiple myeloma and other cancers, through late-stage clinical development. He oversaw the clinical development of Onyx Therapeutics, Inc.'s earlier-stage proteasome inhibitor programs, including PR-047. Dr. Kauffman was Entrepreneur-in-Residence and a Science Advisor at Bessemer Venture Partners since January 2008 to 2011 and an Operating Partner from 2006 to 2008, where he led investments in biotechnology companies. He advised Bessemer Venture Partners life sciences practice and helps evaluate investment opportunities. Dr. Kauffman is based at the Wellesley Hills office and was a part of Healthcare investment team. He served as the President at EPIX Pharmaceuticals, Inc. since 2006 until 2008 and Chief Executive Officer from August 16, 2006 to July 25, 2008. From August 1995 to September 1997, Dr. Kauffman held a number of senior positions at Biogen Idec, Inc. (formerly Biogen Corporation), where Dr. Kauffman served as the Medical Director of the Inflammation Program and in other managerial positions. He led the clinical development of anti-CD40L antibodies in autoimmune and inflammatory diseases, and acted as the main medical advisor to the Biogen business development group. He worked in clinical development and business development at the firm. He served as the President and Chief Executive Officer at Predix Pharmaceuticals Holdings Inc. since August 2003. In that role, he led the merger of Predix Pharmaceuticals and Epix Pharmaceuticals, oversaw the discovery and development of four new clinical candidates and led collaboration transactions with Amgen and GlaxoSmithKline. Dr. Kauffman served as the President and Chief Executive Officer at Predix Pharmaceuticals, Inc from September 2002 to August 2006. Prior to Predix, he served positions of increasing responsibility at Millennium Pharmaceuticals Inc., where Dr. Kauffman served as Vice President of Medicine at Proteasome Inhibitor and Leader of the VELCADE Development Program. From March 2000 to September 2002, he was Vice President, Clinical at Millennium Pharmaceuticals, Inc. He co founded Millennium Predictive Medicine, Inc., and served as its Vice President of Medicine from September 1997 to February 2000, where he co-led collaborations with Becton Dickinson and Bristol-Myers Squibb. Dr. Kauffman established a rheumatology and internal medicine practice at Massachusetts General Hospital. Dr. Kauffman served as the Chairman of Proteolix, Inc. since January 2007. Dr. Kauffman served as an Independent Director of Combinatorx Inc. (also known as Zalicus Inc.) since June 2006. He has been Independent Director of Infinity Pharmaceuticals, Inc. since April 5, 2017. Dr. Kauffman was the Chief Medical Officer of Proteolix, Inc. from November 2008 to November 2009. He has served board of directors of Karyopharm since January 2011 and board of directors of Kezar Life Sciences Inc. He has been a Director of Karyopharm Therapeutics Inc. since 2008. He has been a Director of Metamark Genetics, Inc. since April 2013. He has been Lead Director and Independent Director of Verastem, Inc. since June 14, 2016 and November 26, 2012 respectively. Dr. Kauffman served as a Director of Onyx Therapeutics, Inc. Dr. Kauffman served as a Director of Bioenvision, Inc. since January 26, 2004. He served as a Director of EPIX Pharmaceuticals, Inc. from August 16, 2006 to July 25, 2008. Dr. Kauffman served as a Director of Predix Pharmaceuticals Holdings, Inc. since August 2003. He served as Director of EPIRUS Biopharmaceuticals, Inc. He is the author of numerous medical publications and is the publisher. Dr. Kauffman has written and compiled a medical treatment guide, Outlines in Clinical Medicine® (now owned by Skysacpe Inc.), and published numerous articles in peer-reviewed publications in addition to drug development work. He is board certified in internal medicine and was trained in Internal Medicine at Beth Israel Deaconess and Massachusetts General Hospitals. Dr. Kauffman holds M.D. and a Ph.D. in Biochemistry, Cell and Molecular Biology from Johns Hopkins University in 1992 and performed his postdoctoral training at Harvard University. He received a B.A. Degree in Biochemistry summa cum laude from Amherst College.

CEO Compensation
  • Michael's compensation has increased whilst company is loss making.
  • Michael's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Karyopharm Therapeutics management team in years:

2.9
Average Tenure
49
Average Age
  • The tenure for the Karyopharm Therapeutics management team is about average.
Management Team

Michael Kauffman

TITLE
Co-Founder
COMPENSATION
$3M
AGE
55
TENURE
8.3 yrs

Sharon Shacham

TITLE
Co-Founder
COMPENSATION
$2M
AGE
48
TENURE
5.3 yrs

Chris Primiano

TITLE
Executive VP
COMPENSATION
$1M
AGE
37
TENURE
5.1 yrs

Mansoor Mirza

TITLE
Clinical Consultant
COMPENSATION
$283K
AGE
57
TENURE
9.3 yrs

Mike Mason

TITLE
Senior VP
AGE
43
TENURE
0.2 yrs

Ran Frenkel

TITLE
Chief Development Operations Officer
COMPENSATION
$6M
AGE
49
TENURE
4.3 yrs

Cameron Peters

TITLE
Vice President of Finance
AGE
58
TENURE
0.3 yrs

Ian Karp

TITLE
Vice President of Investor & Public Relations
TENURE
0.8 yrs

Joan Wood

TITLE
Senior VP & Chief Human Resources Officer
TENURE
1.6 yrs

Brian Austad

TITLE
Senior Vice President of Pharmaceutical Sciences
TENURE
1.2 yrs
Board of Directors Tenure

Average tenure and age of the Karyopharm Therapeutics board of directors in years:

5
Average Tenure
55
Average Age
  • The tenure for the Karyopharm Therapeutics board of directors is about average.
Board of Directors

Michael Kauffman

TITLE
Co-Founder
COMPENSATION
$3M
AGE
55
TENURE
11.3 yrs

Sharon Shacham

TITLE
Co-Founder
COMPENSATION
$2M
AGE
48

Giulio Draetta

TITLE
Chairman of Scientific Advisory Board

Mansoor Mirza

TITLE
Clinical Consultant
COMPENSATION
$283K
AGE
57

Barry Greene

TITLE
Lead Independent Director
COMPENSATION
$198K
AGE
55
TENURE
4.3 yrs

Deepa Pakianathan

TITLE
Independent Director
COMPENSATION
$163K
AGE
53
TENURE
6 yrs

Garen Bohlin

TITLE
Independent Director
COMPENSATION
$171K
AGE
71
TENURE
5.5 yrs

J. Garland

TITLE
Independent Director
COMPENSATION
$157K
AGE
49
TENURE
4.4 yrs

Chris Kirk

TITLE
Member of Scientific Advisory Board
AGE
46

Mikael Dolsten

TITLE
Independent Director
COMPENSATION
$153K
AGE
59
TENURE
4.1 yrs
Who owns this company?
Recent Insider Trading
  • Karyopharm Therapeutics insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
05. Mar 19 Sell Wiaczeslaw Smolokowski Individual 28. Feb 19 28. Feb 19 -149,624 €3.63 €-543,644
28. Feb 19 Sell Wiaczeslaw Smolokowski Individual 25. Feb 19 27. Feb 19 -1,481,643 €4.40 €-6,267,583
07. Sep 18 Sell Wiaczeslaw Smolokowski Individual 05. Sep 18 06. Sep 18 -164,800 €18.13 €-2,985,883
04. Sep 18 Sell Wiaczeslaw Smolokowski Individual 30. Aug 18 04. Sep 18 -251,468 €18.22 €-4,557,176
30. Aug 18 Sell Wiaczeslaw Smolokowski Individual 27. Aug 18 29. Aug 18 -214,026 €16.75 €-3,572,237
14. Aug 18 Sell Wiaczeslaw Smolokowski Individual 10. Aug 18 10. Aug 18 -702 €16.20 €-11,375
10. Aug 18 Sell Wiaczeslaw Smolokowski Individual 07. Aug 18 09. Aug 18 -80,876 €16.08 €-1,294,639
25. Jul 18 Sell Wiaczeslaw Smolokowski Individual 23. Jul 18 25. Jul 18 -30,039 €15.99 €-479,867
23. Jul 18 Sell Wiaczeslaw Smolokowski Individual 19. Jul 18 20. Jul 18 -126,742 €16.41 €-2,053,038
18. Jul 18 Sell Wiaczeslaw Smolokowski Individual 16. Jul 18 18. Jul 18 -50,000 €15.92 €-795,399
X
Management checks
We assess Karyopharm Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Karyopharm Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

25K News

Simply Wall St News

25K Company Info

Description

Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase IIb clinical study in treatments of refractory multiple myeloma; Phase Ib/II clinical study in combination with backbone treatments for multiple myeloma patients; Phase III clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; Phase IIb clinical study in diffuse large B-cell lymphoma; Phase II/III clinical study in liposarcoma; Phase III clinical trial in endometrial cancer; and Phase II clinical trial in glioblastoma multiforme. The company is also developing KPT-8602 that is in Phase I/II study for patients with relapsed/refractory multiple myeloma; KPT-9274, which is in Phase I clinical trial for patients with advanced solid malignancies or non-Hodgkin’s lymphoma; KPT-335 that is in Phase IIb clinical trial for the treatment of pet dogs with cancer, as well as Phase I clinical trial for the treatment of viral indications; and KPT-350 that is in preclinical stage to treat neurological disorders, and inflammatory and autoimmune diseases. Karyopharm Therapeutics Inc. was founded in 2008 and is headquartered in Newton, Massachusetts.

Details
Name: Karyopharm Therapeutics Inc.
25K
Exchange: DB
Founded: 2008
$264,298,374
60,864,445
Website: http://www.karyopharm.com
Address: Karyopharm Therapeutics Inc.
85 Wells Avenue,
2nd Floor,
Newton,
Massachusetts, 02459,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS KPTI Common Stock Nasdaq Global Select US USD 06. Nov 2013
DB 25K Common Stock Deutsche Boerse AG DE EUR 06. Nov 2013
Number of employees
Current staff
Staff numbers
332
Karyopharm Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/24 22:36
End of day share price update: 2019/04/24 00:00
Last estimates confirmation: 2019/04/05
Last earnings filing: 2019/02/28
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.